Physician profile
Zorayda E Pretto
NPI 1053371484
$1,936.87
in general payments reported to CMS, 2019-2025
11 companies · $622 in 2025
The $622 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $111 · 2021: $186 · 2022: $532 · 2023: $107 · 2024: $148 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $493.21 | 2019-2025 | Freestyle Libre |
| Novo Nordisk INC | $456.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $277.82 | 2020-2023 | Jardiance |
| Amgen INC. | $263.40 | 2022-2025 | Evenity, Prolia |
| Antares Pharma, INC. | $212.03 | 2019-2025 | Xyosted |
| Beta Bionics, INC. | $108.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $34.93 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $32.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2021-2022 | |
| Medtronic, INC. | $14.92 | 2021 | |
| Insulet Corporation | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zorayda Pretto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.